Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.64 |
| ▸ | MME | P08473 | 3/20 | 0.64 |
| ▸ | ALPI | P09923 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | XIAP | P98170 | 1/20 | 0.61 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.61 |
| ▸ | CTSC | P53634 | 1/20 | 0.60 |
| ▸ | ACE | P12821 | 6/20 | 0.59 |
| ▸ | ANPEP | P15144 | 1/20 | 0.59 |
| ▸ | ECE1 | P42892 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711542 | 1.00 | LTA4H (0.64) | LTA4HMMEALPIPKMPTGS1 | |
| SCHEMBL8787479 | 1.00 | LTA4H (0.64) | LTA4HMMEALPIPKMPTGS1 | |
| SCHEMBL11113147 | 1.00 | LTA4H (0.64) | LTA4HMMEALPIPKMPTGS1 | |
| SCHEMBL30025974 | 1.00 | LTA4H (0.64) | LTA4HMMEALPIPKMPTGS1 | |
| SCHEMBL30051597 | 0.97 | LTA4H (0.61) | LTA4HMMEALPIPKMPTGS1 | |
| SCHEMBL30252512 | 0.97 | LTA4H (0.61) | LTA4HMMEALPIPKMPTGS1 | |
| SCHEMBL8582083 | 0.95 | LTA4H (0.59) | LTA4HMMEALPIPKMPTGS1 | |
| Trifluoroacetic Acid SCHEMBL16050210 | 0.93 | LTA4H (0.57) | LTA4HMMEALPIPKMPTGS1 | |
| SCHEMBL30051113 | 0.93 | OPRD1 (0.60) | LTA4HMMECTSCACEANPEP | |
| SCHEMBL8582077 | 0.92 | LTA4H (0.56) | LTA4HMMEALPIPKMPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 886 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144882-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | BIO-THERA SOLUTIONS, LTD. (CN) | 2026-05-28 | — | — | US | claimed |
| CN-122028936-A | Antibody-drug conjugates | ADC疗法责任有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260008848-A1 | ANTI-NECTIN-4 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | BIO THERA SOLUTIONS LTD (CN) | 2026-01-08 | — | — | US | claimed |
| US-20260007763-A1 | PEGYLATED ANTIBODY HYDROXYL-BEARING DRUG CONJUGATE | SHENZHEN ENDURING BIOTECH, LTD. (CN) | 2026-01-08 | — | — | US | claimed |
| US-20250381283-A1 | METHOD FOR TREATING SOLID TUMOR | BIO THERA SOLUTIONS LTD (CN) | 2025-12-18 | — | — | US | claimed |
| EP-4659592-A1 | FLAVOR ENHANCING COMPOSITION, MANUFACTURING METHOD THEREFOR, AND METHOD FOR ENHANCING FLAVOR OF FOOD PRODUCT | House Foods Corporation (JP) | 2025-12-10 | — | — | EP | claimed |
| EP-4659591-A1 | TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT | House Foods Group Inc. (JP) | 2025-12-10 | — | — | EP | claimed |
| US-20250333498-A1 | ANTI-CLDN18.2 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | BIO THERA SOLUTIONS LTD (CN) | 2025-10-30 | — | — | US | claimed |
| US-20250262314-A1 | MULTIFUNCTIONAL ANTIBODIES | SYNAFFIX B.V. (NL) | 2025-08-21 | — | — | US | claimed |
| EP-3962935-A1 | BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES | Immunogen, Inc. (US) | 2022-03-09 | — | — | EP | claimed |
| EP-3941527-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | ImmunoGen, Inc. (US) | 2022-01-26 | — | — | EP | claimed |
| EP-3805756-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2021-04-14 | — | — | EP | claimed |
| CN-106537145-B | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment | 麦特博隆股份有限公司 | 2020-08-25 | — | — | CN | claimed |
| US-20180275144-A1 | DIAGNOSTIC TOOLS FOR ALZHEIMER'S DISEASE | PHARNEXT (FR) | 2018-09-27 | — | — | US | claimed |
| CN-107667293-A | Diagnostic tool for Ah Hereby sea Mo's disease | 法奈科斯公司 | 2018-02-06 | — | — | CN | claimed |
| EP-3129909-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2017-02-15 | — | — | EP | claimed |
| WO-2016124574-A1 | DIAGNOSTIC TOOLS FOR ALZHEIMER'S DISEASE | PHARNEXT (FR) | 2016-08-11 | — | — | WO | claimed |
| WO-2015157407-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | METABOLON, INC. (US) | 2015-10-15 | — | — | WO | claimed |
| EP-0528629-A2 | Enzymatic synthesis of renin inhibitors | BEND RESEARCH, INC. (US) | 1993-02-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008848-A1 | ANTI-NECTIN-4 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | NECTIN4, VSIG8, IGSF11 | LTA4H 2129/4885MME 3760/4885ALPI 3496/4885 |
| US-20260144882-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | NECTIN4, CD22, NGFR | LTA4H 2691/4885MME 731/4885ALPI 2234/4885 |
| US-20260007763-A1 | PEGYLATED ANTIBODY HYDROXYL-BEARING DRUG CONJUGATE | PTMS, ACP1, CD2 | LTA4H 1050/4885MME 1223/4885ALPI 2180/4885 |
| US-20250333498-A1 | ANTI-CLDN18.2 ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | CNTN1, EPCAM, SLC22A8 | LTA4H 2553/4885MME 2048/4885ALPI 182/4885 |
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | VEGFA, VIP, AREG | LTA4H 3127/4885MME 961/4885ALPI 1313/4885 |
| US-20250381283-A1 | METHOD FOR TREATING SOLID TUMOR | TPM4, TPM3, TPST2 | LTA4H 2803/4885MME 1281/4885ALPI 2912/4885 |
| US-20250262314-A1 | MULTIFUNCTIONAL ANTIBODIES | C1S, APOL1, BTN3A1 | LTA4H 584/4885MME 941/4885ALPI 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.